Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Keith Thomas Flaherty, M.D.

Co-Author

This page shows the publications co-authored by Keith Flaherty and Frank Hodi.
Connection Strength

1.538
  1. Author Correction: From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer. 2020 Dec; 20(12):757.
    View in: PubMed
    Score: 0.234
  2. Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. Melanoma Res. 2018 12; 28(6):605-610.
    View in: PubMed
    Score: 0.203
  3. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014 Jul; 2(7):632-42.
    View in: PubMed
    Score: 0.148
  4. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013 Sep 10; 31(26):3182-90.
    View in: PubMed
    Score: 0.139
  5. From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer. 2012 Apr 05; 12(5):349-61.
    View in: PubMed
    Score: 0.128
  6. Mutation-driven drug development in melanoma. Curr Opin Oncol. 2010 May; 22(3):178-83.
    View in: PubMed
    Score: 0.112
  7. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 2018 11 01; 175(4):984-997.e24.
    View in: PubMed
    Score: 0.051
  8. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov. 2018 02; 8(2):196-215.
    View in: PubMed
    Score: 0.047
  9. A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. Cancer Med. 2017 Aug; 6(8):1904-1914.
    View in: PubMed
    Score: 0.046
  10. An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. Clin Cancer Res. 2016 Nov 01; 22(21):5204-5210.
    View in: PubMed
    Score: 0.044
  11. A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma. Oncologist. 2015 Jun; 20(6):617-8.
    View in: PubMed
    Score: 0.040
  12. Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma. Mol Cancer Ther. 2014 Dec; 13(12):3210-8.
    View in: PubMed
    Score: 0.038
  13. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res. 2014 Jul; 2(7):643-54.
    View in: PubMed
    Score: 0.037
  14. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer. 2014 Jun 01; 120(11):1695-701.
    View in: PubMed
    Score: 0.037
  15. A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J. 2014 Jan-Feb; 20(1):18-24.
    View in: PubMed
    Score: 0.036
  16. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer. 2013 Oct 15; 119(20):3687-95.
    View in: PubMed
    Score: 0.035
  17. Ipilimumab for patients with advanced mucosal melanoma. Oncologist. 2013 Jun; 18(6):726-32.
    View in: PubMed
    Score: 0.035
  18. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013 Mar 01; 19(5):1225-31.
    View in: PubMed
    Score: 0.034
  19. Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med. 2012 Jul 04; 10:83.
    View in: PubMed
    Score: 0.033
  20. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma. Arch Dermatol. 2012 Mar; 148(3):363-6.
    View in: PubMed
    Score: 0.032
  21. Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma. J Clin Oncol. 2011 May 20; 29(15_suppl):8508.
    View in: PubMed
    Score: 0.030
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.